CIK 0001512762 · Accelerated filer<br>Smaller reporting company
Coherus Oncology, Inc.
Sign in to watch- Ticker
- CHRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273615821
- Phone
- (650) 649-3530
- Business address
- C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA, 94065
- Former names
- Coherus BioSciences, Inc., BioGenerics, Inc.
- 4 Shares withheld for taxes Chief Scientific Officer gave up 7,733 shares (to pay taxes)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- SC 13G/A Stake Amended Statement of Ownership
- 8-K Event Material agreement · Agreement ended · New debt or obligation · Other events
- 4 Grant or award President & CEO acquired 86,250 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 40,000 shares (grant or award)
- 4 Grant or award Chief Scientific Officer acquired 40,000 shares (grant or award)
- CORRESP Other Correspondence Between Filers and SEC Staff
- UPLOAD Other SEC-generated Letter
- 8-K Event Executive or director change
- 4 Gift President & CEO gave 10,000 shares (gift)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Open-market sale Chief Financial Officer sold 3,507 shares at $16.80 ($58,919)
- 8-K Event Executive or director change
- 4 Open-market sale Director sold 434,555 shares at an average $16.68 ($7,250,063)
- 8-K Event Executive or director change
Page 17 of 47 · 923 filings